Table of Contents
- 01Introduction
- 02Why Two Agencies Instead of One
- 03What the DEA Side Actually Involves
- 04How This Differs From Ordinary Controlled-Substance Regulatory Work
- 05What Employers Are Actually Looking For
- 06How Other Countries Handle the Same Split
- 07Common Mistakes Sponsors Make
- 08Where These Roles Sit Organizationally
- 09Career Considerations for Anyone Weighing This Path
- 10Conclusion
Introduction
Most drugs clear one regulatory gate on their way to a prescription pad: FDA review of safety and efficacy. Cannabinoid-derived drugs clear two, and the two gates don't always open in the same order or on the same timeline. Because cannabis and many of its derivatives are still listed under the Controlled Substances Act, a cannabinoid drug program has to satisfy the FDA's standard drug development pathway while simultaneously managing DEA scheduling, registration, and quota requirements that most other therapeutic areas never touch. The result is a small but growing hiring niche for regulatory professionals who can hold both systems in their head at once, and employers in this space routinely say that finding people who already understand both is harder than finding people who understand either one alone.
Why Two Agencies Instead of One
The split exists because of how federal law defines the substance, not because of how the drug performs clinically. Cannabis and many cannabinoids remain Schedule I or Schedule II controlled substances depending on their chemistry and source, regardless of what an NDA submission shows about their therapeutic benefit. That means a sponsor developing a cannabinoid drug is running two regulatory tracks in parallel: the FDA track, which evaluates the chemistry, manufacturing, controls, and clinical evidence the same way it would for any other new molecular entity, and the DEA track, which governs who may grow, synthesize, possess, transport, and study the active substance at every stage from early research through commercial manufacturing. A single FDA approval does not resolve the DEA side of the equation. In several cases, a drug has received FDA approval and then had to wait for a separate DEA scheduling action before it could actually reach pharmacy shelves, because the approved product itself still needed to be placed into a schedule under the Controlled Substances Act.
160 open now
Regulatory affairs roles
Associate Director, Global Regulatory Affairs, InflammationTakedaCambridge, MA · Hybrid$154K–$243K
Associate Director, Regulatory Affairs - In Vitro Diagnostics and Digital HealthRegeneronRemote, US$180K–$293K
Director, Regulatory AffairsHumacyteDurham, NC · Hybrid
VP, Regulatory Affairs Strategy4D Molecular TherapeuticsEmeryville, CA · Hybrid$326K–$381K
What the DEA Side Actually Involves
For regulatory staff who have only worked on conventional small molecules or biologics, the DEA requirements are the unfamiliar part of the job. Research-stage work requires DEA registration for every facility that handles the controlled substance, along with security and recordkeeping standards that go well beyond what GMP alone demands. As a program moves from early research into larger clinical trials and eventually commercial manufacturing, the quota system becomes a live planning constraint: DEA sets annual production quotas for many controlled substances, and a sponsor that doesn't request and justify quota early enough can find its own regulatory approval outpacing its legal ability to manufacture at scale. Import and export of cannabinoid active pharmaceutical ingredients adds another layer, since international sourcing of cannabis-derived material typically requires DEA import permits in addition to the usual FDA and customs paperwork. None of this is exotic to someone who has spent a career in controlled-substance work, but it is largely invisible to a regulatory affairs professional who has only ever worked on non-scheduled drugs.
How This Differs From Ordinary Controlled-Substance Regulatory Work
Sponsors already working with opioids, stimulants, or other scheduled drugs have regulatory staff who understand DEA registration and quota mechanics. What makes cannabinoid programs their own niche, rather than simply an extension of that existing controlled-substance expertise, is the added complexity of state-level cannabis law running alongside the federal framework. A regulatory professional on a cannabinoid drug program has to track not only FDA and DEA requirements but also how state cannabis statutes intersect with federal controlled-substance law, particularly for sponsors that also have state-licensed cannabis operations or that are sourcing material from state-regulated growers. The legal landscape for cannabis-derived material has shifted multiple times in recent years as federal rescheduling discussions have moved forward and stalled, and a regulatory team that isn't actively monitoring that landscape can find its sourcing or manufacturing assumptions invalidated with little warning.
What Employers Are Actually Looking For
Job postings in this niche tend to describe a hybrid profile rather than a single credential: CMC or regulatory affairs experience on the FDA side, paired with direct exposure to DEA registration, quota requests, or security and diversion-control compliance. Candidates who have worked at a company handling Schedule II stimulants, opioids, or other controlled substances and who can speak fluently about quota planning and DEA inspections tend to be strong fits even without prior cannabis-specific experience, because the DEA mechanics transfer directly. Candidates coming from the cannabis industry's state-licensed side bring real value in understanding the plant material, cultivation, and extraction landscape, but often need to build FDA drug-development fluency from the ground up, since state cannabis licensing and FDA drug approval are governed by entirely different standards. The strongest hires tend to be the ones who have sat in rooms where both conversations happened, whether that's a pharmaceutical company with an established controlled-substances program branching into cannabinoids, or a cannabis-focused company bringing on its first regulatory affairs lead with pharmaceutical development experience.
How Other Countries Handle the Same Split
The United States is not unique in regulating cannabinoid drugs through two separate systems, which matters for any regulatory professional working on a multi-market cannabinoid program. Canada manages the same tension through its Cannabis Act alongside the Controlled Drugs and Substances Act, with Health Canada requiring separate licensing for cultivation, processing, and sale depending on whether the product is positioned as a conventional pharmaceutical or under the country's broader cannabis framework. The United Kingdom treats most cannabis-derived substances as controlled drugs under the Misuse of Drugs Act, which means a sponsor seeking MHRA approval for a cannabinoid medicine still has to secure a Home Office controlled-drug license for any UK-based handling, research, or manufacturing, mirroring the FDA-DEA split in structure even though the specific agencies and statutes differ. Australia's Therapeutic Goods Administration similarly coordinates with that country's separate narcotic drugs licensing regime. None of these frameworks are identical to the US system, and a regulatory professional managing a global cannabinoid program needs to learn each jurisdiction's version of the split rather than assuming the DEA playbook transfers directly, but the underlying pattern, two regulators answering two different questions about the same molecule, repeats across most developed markets.
Common Mistakes Sponsors Make
Programs new to this space tend to make a predictable set of errors, and regulatory professionals who can help a sponsor avoid them are valuable precisely because the mistakes are expensive. The most common is sequencing: treating DEA registration and quota requests as something to start after FDA interactions are well underway, rather than in parallel from early development, which routinely leaves an approved or soon-to-be-approved drug unable to reach commercial quantities on schedule. A second common error is underestimating how long state-level cannabis licensing questions take to resolve when a sponsor's supply chain touches state-licensed cultivators, since state processes run on entirely separate timelines from federal drug development. A third is assuming that import and export of cannabinoid material follows the same customs and FDA import-alert procedures as ordinary pharmaceutical ingredients, when in practice DEA import and export permitting adds its own separate approval step that has to be built into the supply chain timeline well in advance of when material is actually needed.
Where These Roles Sit Organizationally
Because the DEA relationship is distinct from ordinary FDA interactions, some sponsors create a dedicated controlled-substances regulatory function that reports alongside, rather than inside, the main regulatory affairs team. Smaller companies more often fold DEA responsibilities into a single regulatory affairs hire who owns both sides of the relationship personally, which is demanding but also builds exactly the dual-system fluency that makes someone valuable to the next cannabinoid-focused employer. Larger, more established pharmaceutical companies entering the space sometimes staff a hybrid team: a CMC-focused regulatory lead who owns the FDA submission and an experienced controlled-substances compliance specialist who owns DEA registration, quota, and security requirements, with both reporting into the same program lead to keep the two tracks synchronized.
Career Considerations for Anyone Weighing This Path
This remains a specialized, relatively small niche compared to larger hiring categories like oncology or medical devices, so candidates should weigh depth against breadth. The upside is genuine scarcity value: there are not many regulatory professionals who can speak credibly to both FDA drug development and DEA controlled-substance compliance, and that combination travels well to adjacent work in opioid-sponsor regulatory roles, psychedelic-assisted therapy programs facing similar dual-track requirements, or any other substance that sits at the intersection of drug approval and federal scheduling. The downside is that the cannabinoid drug space is still comparatively young and its federal legal footing has shifted before and could shift again, which means career planning here benefits from staying genuinely interested in the controlled-substances regulatory discipline itself, not just the current wave of cannabinoid drug development.
Conclusion
Cannabinoid drug programs are a reminder that regulatory affairs work is defined as much by the legal classification of a substance as by its clinical profile. The professionals who thrive in this niche are the ones comfortable holding two regulatory relationships at once, translating between an FDA review division focused on safety and efficacy and a DEA office focused on diversion control and scheduling. For regulatory affairs professionals with controlled-substance experience looking for a growth area, or pharmaceutical CMC specialists curious about a genuinely different kind of regulatory complexity, this is a niche worth understanding before the hiring demand for it becomes more widely recognized.
Regulatory & Quality. REWIRED.
New roles. Real pay. Your next move.
- Hand-picked roles, every week.
- The newest company pages.
- One article worth your time.
Free. Thursday mornings. One-click unsubscribe.
About the author
Connor GriggsMSRA, CQA
Founder & Editor-in-Chief
Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.
Find your next regulatory or quality role
Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.
